Media stories about Curis (NASDAQ:CRIS) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Curis earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.92523382245 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Cowen & Co. Keeps a Buy Rating on Curis Inc (CRIS) (analystratings.com)
- Notable Price Swings: Bellerophon Therapeutics, Inc. (BLPH), Curis, Inc. (CRIS) (talktraders.com)
- Curis, Inc. (CRIS) Top Loser within Investor Spotlight: (topdesertsafari.com)
- Contrasting Biogen (BIIB) & Curis (CRIS) (americanbankingnews.com)
- Curis (CRIS) Rating Reiterated by Cowen (americanbankingnews.com)
Shares of Curis traded up $0.01, reaching $1.61, during mid-day trading on Friday, according to MarketBeat.com. 145,319 shares of the company’s stock were exchanged, compared to its average volume of 266,878. The firm has a market cap of $53.09 million, a P/E ratio of -0.89 and a beta of 0.98. The company has a debt-to-equity ratio of 4.43, a current ratio of 3.01 and a quick ratio of 3.01. Curis has a twelve month low of $1.57 and a twelve month high of $11.35.
CRIS has been the topic of a number of research analyst reports. Zacks Investment Research raised Curis from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Tuesday, May 8th. Cowen reaffirmed a “buy” rating on shares of Curis in a research report on Monday, August 6th. SunTrust Banks dropped their price target on Curis to $8.00 and set a “buy” rating on the stock in a research report on Friday, August 3rd. ValuEngine lowered Curis from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Finally, Robert W. Baird dropped their price target on Curis to $30.00 and set an “outperform” rating on the stock in a research report on Monday, May 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Curis has a consensus rating of “Buy” and an average price target of $18.75.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Recommended Story: Should you buy a closed-end mutual fund?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.